期刊
DEPRESSION AND ANXIETY
卷 27, 期 10, 页码 960-963出版社
WILEY
DOI: 10.1002/da.20731
关键词
depression; transcranial magnetic stimulation; repetitive; clinical trial
资金
- Fuqua Family Foundation [B3357R]
- US. Department of Veterans Affairs [C4850C]
- Rehabilitation Research and Development Centers of Excellence
- National Institutes of Health National Center for Research Resources [M01 RR00039]
- Dana Foundation [UL1 RR025008]
- Greenwall Foundation
- NARSAD
- National Institute of Mental Health (NIMH) [K23 MH077869]
- National Institutes of Health Loan Repayment Program
- Northstar, Inc.
- Stanley Medical Research Institute
- Woodruff Foundation
- NIMH [R01 MH069886]
- National Institute of Neurological Disease and Stroke [R01 NS046487]
- GlaxoSmithKline, Inc.
- UCB, Inc.
Background: Repetitive transcranial magnetic stimulation (rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks. Accelerated TMS, with all treatments delivered over a few days, would have significant advantages in terms of access and patient acceptance. Methods: Open-label accelerated TMS (aTMS), consisting of 15 rTMS sessions administered over 2 days, was tested in 14 depressed patients not responding to at least one antidepressant medication. Effects on depression, anxiety, and cognition were assessed the day following treatment, then after 3 and 6 weeks. Results: No seizure activity was observed and only one patient had a serious adverse event (increased suicidal ideation). Two patients failed to complete a full course of aTMS treatments, and 36% did not complete all study visits. Depression and anxiety significantly decreased following aTMS treatments and improvements persisted 3 and 6 weeks later. Response rates immediately following treatment and at 3 and 6 weeks were 43, 36, and 36%, respectively. Remission rates at the same timepoints were 29, 36, and 29%. Conclusions: Accelerated TMS demonstrated an excellent safety profile with efficacy comparable to that achieved in daily rTMS in other trials. Limitations primarily include open-label treatment and a small sample size. Depression and Anxiety 27: 960-963, 2010. (C) 2010 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据